Skip to main content

Table 1 Weibull distribution parameters

From: Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

Group

λ

γ

AIC

(Weibull)

AIC

(Exponential)

OS (durvalumab plus chemotherapy)

0.0156467

1.2807604

− 1549.654

− 1028.268

OS (chemotherapy alone)

0.009309

1.5330827

− 2404.491

− 927.0487

PFS (durvalumab plus chemotherapy)

0.029721

1.397684

− 1041.413

− 731.1559

PFS (chemotherapy alone)

0.0167583

1.754329

− 1559.848

− 709.4789

  1. PFS progression-free survival, OS overall survival